Natalizumab use in multiple sclerosis and single-center clinical experience

Puntos clave

• Natalizumab demonstrates significant reductions in relapse rates in multiple sclerosis patients, leading to better overall control of the disease.
• In the observed cohort, 80% of patients showed decreased relapse frequency over a 12-month period while on natalizumab treatment.
• The analysis involved clinical assessments and patient-reported outcomes from a single-center cohort of MS patients.
• These findings support the potential of natalizumab as an effective therapeutic option for multiple sclerosis management.